Intake Forms for Medical Spas: Documentation Every Med Spa Needs Before the First Injection
A patient sits in your treatment room, ready for her first round of Botox. She filled out a one-page form at the front desk — name, date of birth, a checkbox asking if she is pregnant. Your injector glances at it, confirms the treatment area, and reaches for the syringe. Nobody asked about her history of keloid scarring. Nobody documented that she took aspirin this morning. Nobody screened for the autoimmune condition that makes neurotoxin injections medically inadvisable. If something goes wrong, your documentation will not protect you. It will bury you.
Medical spas occupy a uniquely complex regulatory space. You are performing medical procedures — injections, laser treatments, chemical peels — in a setting that feels like a luxury retail experience. Patients expect a spa atmosphere, but the treatments carry medical risks: vascular occlusion from filler, burns from improperly calibrated lasers, allergic reactions to topical anesthetics, and systemic complications in patients whose medical histories were never properly screened. Your medical spa intake form is the single document that bridges this gap between the patient experience and the clinical reality.
I have reviewed intake documentation for med spas that ranged from a single waiver printed from the internet to forty-page packets that no patient actually reads. Neither approach works. What works is a structured, procedure-aware intake process that captures the specific clinical information your providers need to treat safely, documents informed consent in a way that actually holds up, and satisfies the regulatory framework your medical director is personally liable for. Here is what that documentation looks like, section by section.
Medical history screening for aesthetic contraindications
General medical intake forms ask about diabetes, heart disease, and surgical history. Those questions matter, but they miss the contraindications specific to aesthetic medicine. A patient with well-controlled hypertension on lisinopril is not the same risk profile as a patient with well-controlled hypertension on lisinopril who also has a history of angioedema — because angioedema is a contraindication for hyaluronic acid dermal fillers, and lisinopril itself increases angioedema risk. Your intake form needs to capture medical history through the lens of what you actually do to patients.
The conditions that matter most in aesthetic medicine often are not the ones patients think to mention:
- Autoimmune disorders — lupus, scleroderma, rheumatoid arthritis, dermatomyositis. These conditions affect wound healing, increase risk of granuloma formation from fillers, and may flare in response to tissue trauma from injections or laser treatments. A patient with active lupus who receives aggressive laser resurfacing is at significant risk for post-inflammatory hyperpigmentation, delayed healing, and disease flare.
- Bleeding disorders and anticoagulant use — hemophilia, von Willebrand disease, current use of warfarin, apixaban, clopidogrel, or even daily aspirin or fish oil. These do not necessarily contraindicate treatment, but they require adjusted techniques (smaller gauge needles, reduced injection pressure, extended post-injection compression) and honest counseling about bruising risk. The patient who shows up to her sister's wedding with bilateral periorbital ecchymoses after under-eye filler will not care that you technically performed the injection correctly.
- History of herpes simplex virus (HSV) — perioral filler injections and laser resurfacing around the mouth can reactivate latent HSV, causing a herpetic outbreak that in rare cases progresses to disseminated herpes. Standard of care requires antiviral prophylaxis (valacyclovir 500mg BID starting 2 days before and continuing 5 days after treatment) for any patient with a history of cold sores receiving perioral procedures. If your intake form does not ask about cold sore history, your provider cannot prescribe prophylaxis, and you are below the standard of care before the procedure begins.
- Keloid and hypertrophic scarring history — patients with a history of keloid formation are poor candidates for procedures that create controlled tissue injury: microneedling, ablative lasers, deep chemical peels. This is a conversation, not just a checkbox — keloid tendency varies by body location and severity, and a patient who scarred on her earlobes may do fine with facial microneedling. But you need to know before you start.
- Active skin conditions — eczema, psoriasis, rosacea, active acne, perioral dermatitis. These conditions change treatment selection, contraindicate certain procedures during active flares, and require modified aftercare protocols. A patient with active rosacea who receives an IPL treatment calibrated for a normal skin type may experience a dramatic inflammatory response rather than the desired improvement.
- History of radiation therapy — patients who have received radiation to the face or neck have compromised tissue vascularity and healing capacity in the irradiated field. Filler injections in previously irradiated tissue carry increased risk of tissue necrosis, and laser treatments must be significantly detuned.
- Dental procedures — recent or planned — dental work within two weeks of facial filler injections increases infection risk. Conversely, filler placed in the perioral region may migrate or distort during subsequent dental procedures. Your intake should ask about recent dental work and planned procedures so your provider can sequence treatments appropriately.
This is not an exhaustive list — it is the minimum. Your medical director should review the intake form quarterly and add conditions as the practice expands its treatment menu. When you add a new laser platform or a new injectable product, the contraindication profile of that product must be reflected in your intake screening.
Skin type assessment: the Fitzpatrick scale and treatment planning
The Fitzpatrick skin phototype classification is not optional in aesthetic medicine. It is the foundation of every laser parameter setting, chemical peel depth decision, and post-inflammatory hyperpigmentation risk assessment your providers make. A Fitzpatrick Type II patient and a Fitzpatrick Type V patient receiving the same IPL treatment at the same settings will have dramatically different outcomes — the Type V patient may develop hyperpigmentation that takes months to resolve, or worse, hypopigmentation that may be permanent.
Your intake form should guide both the patient and the provider through a structured skin type assessment:
- Fitzpatrick classification (I through VI) — based on the patient's response to UV exposure: does unexposed skin burn easily? Does it tan? What is the baseline color of unexposed skin? Most patients do not know their Fitzpatrick type, so the form should ask the component questions rather than expecting the patient to self-classify.
- Ethnic background — relevant because melanin distribution patterns and post-inflammatory hyperpigmentation risk correlate with ethnic heritage, even among patients who appear to have lighter skin. A patient of South Asian descent with relatively light skin may still carry melanocyte reactivity patterns that affect laser treatment planning.
- Sun exposure history and tanning habits — current tan status, history of tanning bed use, outdoor occupation, recent sun exposure. A patient who is Fitzpatrick III but returned from a Caribbean vacation two weeks ago is functionally a higher type for laser treatment purposes until that tan fades. Many practices will not treat patients with an active tan, and your intake documentation should capture this so the provider can reschedule rather than proceeding at inappropriate settings.
- History of post-inflammatory hyperpigmentation (PIH) — has the patient experienced dark spots after acne, cuts, or previous cosmetic treatments? A positive PIH history signals heightened melanocyte reactivity and requires more conservative laser settings, modified chemical peel formulations, and potentially pre-treatment with tyrosinase inhibitors.
- Current skincare regimen — specifically retinoid use (tretinoin, adapalene, tazarotene), hydroquinone, alpha hydroxy acids, and vitamin C serums. Retinoids thin the stratum corneum and increase photosensitivity, which changes both chemical peel depth and laser treatment parameters. Hydroquinone is relevant because it indicates the patient is already concerned about pigmentation and may be a more complex treatment candidate. A patient on high-strength tretinoin who receives a medium-depth TCA peel without an adequate retinoid washout period will experience significantly more erythema, peeling, and potential scarring than expected.
Injectable consent documentation: Botox, fillers, and neurotoxins
Injectable consent in a medical spa is not a generic "I understand the risks" signature. Each injectable category — neurotoxins (Botox, Dysport, Xeomin, Jeuveau), hyaluronic acid fillers (Juvederm, Restylane, RHA, Versa), biostimulatory fillers (Sculptra, Radiesse), and combination treatments — carries distinct risk profiles that require specific consent language.
Your consent documentation for injectables should address:
- Product-specific identification — the exact product being injected, the manufacturer, and the lot number. This is not just a regulatory requirement — it is critical for adverse event tracking. If a patient develops a granuloma six months after filler injection, you need to know exactly which product and lot was used. Generic consent that says "dermal filler" without specifying the product is inadequate.
- Treatment area documentation — the specific injection sites: glabellar complex, lateral canthal lines, forehead, nasolabial folds, marionette lines, lips, chin, jawline, temples, tear troughs, cheeks. Each area carries its own risk profile. Tear trough filler has a higher complication rate than cheek augmentation. Glabellar filler carries vascular occlusion risk that nasolabial fold filler does not (or more precisely, carries a different vascular occlusion risk involving the retinal artery). The consent must be area-specific.
- Vascular occlusion risk disclosure — particularly for filler. Vascular occlusion is the most serious complication of dermal filler injection, potentially causing tissue necrosis or, in the case of retrograde arterial flow, vision loss. Your consent must explicitly state this risk, and your intake form must document whether the patient has previously received filler in the same area (which may alter vascular anatomy due to compression or displacement of prior product).
- Previous injectable history — what products has the patient received before? When? Where? Any complications? Residual filler from a previous injection — particularly if the patient does not remember or disclose the product — can interact unpredictably with new product. Permanent fillers (silicone, PMMA) that the patient received years ago at another practice are still in the tissue and create complications that your provider must anticipate.
- Expected duration and retreatment timeline — neurotoxins last 3–4 months. HA fillers last 6–18 months depending on the product and treatment area. Biostimulatory fillers work over 2–3 months and last 2+ years. Setting accurate expectations at the consent stage reduces patient dissatisfaction and "it didn't work" complaints that are actually just unrealistic expectations about product longevity.
- Post-treatment restrictions — no lying flat for 4 hours after neurotoxin, no vigorous exercise for 24 hours, no dental procedures for 2 weeks after perioral filler, no flying for 48 hours after certain filler treatments (cabin pressure changes can exacerbate swelling). These restrictions must be documented as disclosed so you have a defense when the patient who went to her spin class three hours after Botox develops unexpected diffusion.
Laser treatment protocols and photosensitivity screening
Laser treatments in a medical spa — IPL, Nd:YAG, alexandrite, diode, CO2 fractional, erbium — are medical procedures that cause controlled tissue injury. The difference between a successful treatment and a burn is calibration, and calibration depends entirely on information captured at intake.
Your laser screening must document:
- Photosensitizing medications — this is the most frequently missed screening element in medical spa intakes. Doxycycline, minocycline (commonly prescribed for acne — exactly the patient population seeking laser treatment), isotretinoin (Accutane — requires a 6-month washout before laser treatment), fluoroquinolones, thiazide diuretics, amiodarone, St. John's Wort, certain NSAIDs. A patient on doxycycline for acne who receives an IPL treatment will experience an exaggerated photothermal reaction that can cause burns, blistering, and permanent scarring. Your intake form must list the major photosensitizing drug classes and require the patient to disclose current use.
- Isotretinoin (Accutane) history — this deserves its own line on the form, separate from the general photosensitizer screening, because isotretinoin fundamentally alters wound healing for months after discontinuation. Most laser manufacturers and dermatology guidelines recommend a 6–12 month waiting period after completing isotretinoin before performing ablative laser procedures. The intake must capture: has the patient ever taken isotretinoin? When was the last dose? What was the daily dosage and duration? A patient who completed Accutane three months ago is not a candidate for CO2 fractional resurfacing, regardless of what she read on social media.
- Previous laser treatment history — what devices? What settings (if known)? Any adverse reactions? Treatment intervals? A patient who had aggressive IPL at another practice two weeks ago may have residual inflammation that makes retreatment dangerous. A patient who experienced paradoxical hypertrichosis after laser hair removal (it happens, particularly in patients with fine vellus hair on the face and neck) needs a different approach.
- Recent skin treatments — chemical peels, microdermabrasion, microneedling, waxing, or electrolysis within the past 2–4 weeks. These procedures compromise the skin barrier and change the tissue response to laser energy. Timing matters, and your intake form needs to capture recent treatment history so your provider can determine whether adequate healing time has elapsed.
- Tattoos in the treatment area — laser energy is absorbed by tattoo pigment, which can cause burns, pigment dispersion, and tissue damage. Hair removal lasers used over a tattoo will burn the patient. Your form must ask about tattoos in or near any planned treatment area.
- Metal implants — some laser and radiofrequency devices interact with metal implants (dental implants, orthopedic hardware, intradermal piercings). While not all devices are affected, the screening question should be on the form so the provider can assess compatibility with the specific device being used.
- History of seizure disorders — certain laser treatments produce bright flashes that can trigger photosensitive seizures. This is uncommon but catastrophic when it occurs. The question takes one line on your intake form. Not asking it is indefensible.
Chemical peel depth classification and aftercare agreements
Chemical peels in a medical spa range from superficial (glycolic, lactic, salicylic — minimal downtime) to medium-depth (TCA 25–35%, Jessner's + TCA) to deep (phenol-based — rarely performed in a spa setting and requiring cardiac monitoring). The consent and intake documentation must be calibrated to the depth of the peel, because the risk profile changes dramatically at each level.
- Previous peel history — what acids, what concentrations, what reactions? A patient who tolerated a 30% glycolic peel without complications is different from a patient whose first peel experience is at your practice. Previous tolerance informs concentration selection.
- Active retinoid use and washout status — retinoids increase acid penetration depth. A patient on tretinoin 0.1% who receives a 35% TCA peel will experience deeper penetration than intended, potentially converting a medium-depth peel into a deep peel with attendant scarring risk. Your intake must capture retinoid use and document whether an adequate washout period (typically 5–7 days for superficial peels, 2+ weeks for medium-depth) has been observed.
- History of poor wound healing — diabetes, peripheral vascular disease, current corticosteroid use, nutritional deficiencies, smoking. All of these impair the re-epithelialization process that chemical peels depend on for a good outcome.
- Aftercare compliance assessment — medium and deep peels require strict sun avoidance, specific moisturizer protocols, and in some cases prescription antiviral or antibiotic prophylaxis. If the patient is a lifeguard, a construction worker, or is leaving for a beach vacation in three days, the timing is wrong for anything beyond a superficial peel. Your intake should capture occupation and upcoming plans so the provider can time the treatment appropriately.
- Signed aftercare agreement — the aftercare protocol should be documented as a signed agreement, not just verbal instructions. When a patient who received a medium-depth TCA peel picks off the peeling skin prematurely (causing scarring) or goes to the beach three days later (causing post-inflammatory hyperpigmentation), your defense depends on documented aftercare instructions and the patient's signed acknowledgment of those instructions.
Before-and-after photography consent and usage rights
Clinical photography is essential in aesthetic medicine for treatment planning, outcome documentation, and — this is the part that creates legal exposure — marketing. Your intake must separate clinical photography consent from marketing usage rights, because they are legally and ethically distinct.
- Clinical photography consent — authorization to take standardized photographs before, during (if relevant), and after treatment for inclusion in the patient's medical record. This is a medical documentation function. The photographs are part of the chart. Most patients consent to this readily, and it should be presented as a standard part of clinical care — because it is.
- Marketing usage authorization — a separate consent, with a separate signature line, authorizing the use of the patient's photographs on the practice's website, social media, printed marketing materials, and third-party review platforms. This consent must specify:
- Whether the patient's name will be used or images will be anonymous
- Whether images will be used on social media (Instagram, TikTok, Facebook), the practice website, printed materials, or all of the above
- Whether the consent is perpetual or time-limited
- Whether the patient can revoke consent and what happens to already-published images upon revocation
- Whether the images may be shared with product manufacturers for case studies or promotional use
- Minor patient photography — if your practice treats patients under 18 (acne treatments, for example), parental or guardian consent for photography is mandatory, and the marketing usage question becomes even more sensitive. Many practices have a blanket policy against marketing use of minor patient images, which simplifies the consent but should still be documented.
The key mistake practices make is burying the marketing consent inside the general treatment consent. A patient who signs a ten-page document that includes, on page seven, a clause authorizing social media use of her photographs has a strong argument that she did not provide meaningful consent when those photos appear on the practice's Instagram. Separate the clinical and marketing consent. Make the marketing consent opt-in, not opt-out. You will get fewer marketing authorizations, but the ones you get will actually hold up.
Product allergy screening: lidocaine, hyaluronic acid, and beyond
Medical spa treatments use a specific set of pharmaceutical products that carry allergy risks distinct from general medication allergies. Your intake form must screen for these specifically, because patients will not volunteer them in response to a general "do you have any drug allergies?" question.
- Lidocaine and other local anesthetics — lidocaine is present in most dermal filler products (Juvederm, Restylane, and most HA fillers now come premixed with lidocaine) and is used as topical anesthetic cream (BLT cream, LMX) before laser treatments. True lidocaine allergy is rare but serious. More common is sensitivity to topical anesthetic formulations that causes contact dermatitis. Your form should ask about previous reactions to local anesthetics including dental anesthetics, which are typically lidocaine or articaine.
- Hyaluronic acid — HA is naturally present in human tissue, so true allergy is extremely rare. However, patients with hypersensitivity to HA-based products (which may be related to the bacterial fermentation source or cross-linking agents rather than the HA itself) need documentation. Also capture whether the patient has had previous HA filler with reactions such as delayed-onset nodules, which may indicate a granulomatous response rather than a true allergy but still affects treatment planning.
- Botulinum toxin sensitivity — patients with known hypersensitivity to botulinum toxin or human albumin (which is used as a stabilizer in some neurotoxin formulations) should not receive botulinum toxin injections. Also screen for cow's milk protein allergy in patients receiving Dysport (abobotulinumtoxinA), which contains lactose derived from cow's milk in its formulation.
- Silicone sensitivity — relevant if your practice uses silicone-based products, silicone sheeting for scar management, or if the patient has silicone implants that may be in the treatment field.
- Latex allergy — your providers may use latex gloves, and some medical devices contain latex components. Document this at intake so the treatment room is set up with non-latex alternatives before the patient arrives.
- Preservative sensitivities — methylparaben, propylparaben, phenoxyethanol, and other preservatives appear in topical products used during and after treatment. Patients with known preservative sensitivities need alternative product selections.
Medical director oversight and delegation documentation
Every medical spa operates under a medical director — a physician (MD or DO) whose license authorizes the medical procedures performed at the practice. The intake documentation must reflect this oversight structure, not just for regulatory compliance but because the medical director's personal liability is on the line for every treatment performed under their supervision.
- Medical director identification — your intake materials should identify the medical director by name, credentials, and specialty. Patients have a right to know which physician is responsible for their care, even if that physician is not the person performing the treatment.
- Treating provider identification and credentials — document who will actually perform the procedure: the medical director personally, a nurse practitioner, a physician assistant, or a registered nurse. The patient's consent must be specific to the provider type, because the scope of procedures each provider type can perform varies by state, and the patient may have a preference.
- Standing orders and treatment protocols — the medical director's standing orders should be referenced in the consent documentation. When a nurse injector administers Botox under a standing order protocol, the patient should understand that the medical director has approved the treatment protocol and dosing guidelines even though the medical director is not in the room.
- Emergency protocol disclosure — your intake should document that the patient has been informed of the emergency protocols in place, including: the presence or availability of hyaluronidase (for dissolving HA filler in vascular occlusion emergencies), epinephrine (for anaphylaxis), and the protocol for emergency medical response. This is both a safety measure and a documentation element that demonstrates your practice operates at a medical standard, not a cosmetic-retail standard.
State-specific scope of practice for injectors
Scope of practice for aesthetic injectors varies dramatically by state, and your intake documentation must comply with your state's specific rules. This is not an area where you can use a nationally standardized form and assume it works everywhere.
- Physician supervision requirements — some states require the medical director to be physically present in the facility when certain procedures are performed. Others allow "general supervision" where the physician is available by phone. A few require the physician to personally evaluate each new patient before any provider performs the first treatment. Your intake process must build in the physician evaluation step where required, and your documentation must prove it happened.
- RN scope limitations — in many states, registered nurses can administer injectables under physician delegation, but the delegation must be documented as a standing order or specific patient order. Some states prohibit RNs from performing certain advanced procedures (deep filler injections, for example) regardless of delegation. Your consent form must accurately represent what the treating provider is authorized to do under your state's nurse practice act.
- NP and PA independent practice considerations — nurse practitioners and physician assistants have broader scope in most states, and in some states can own and operate medical spas independently. But even in independent-practice states, the scope may not cover all aesthetic procedures. Your intake documentation should identify the provider's credential type and the authority under which they are performing the specific procedure.
- Esthetician limitations — licensed estheticians in most states can perform superficial chemical peels, microdermabrasion, and certain non-ablative light-based treatments. They cannot inject anything or perform medium-to-deep chemical peels. Your intake form should route the patient to the appropriate provider type based on the requested treatment, and the consent should be signed by a provider authorized to perform that specific treatment.
Pregnancy and breastfeeding screening protocols
Pregnancy screening is the one area where most medical spa intake forms actually ask a question. But asking "are you pregnant?" is not a screening protocol. It is a single question that misses the nuance of how pregnancy, breastfeeding, and fertility treatment affect aesthetic medicine decisions.
- Current pregnancy status — direct question: are you currently pregnant or do you believe you may be pregnant? This is the baseline, and it contraindicate neurotoxins (Botox, Dysport), most dermal fillers (category C or insufficient data), chemical peels beyond superficial glycolic, and most laser treatments. The standard of care is to defer all elective aesthetic procedures in pregnant patients.
- Breastfeeding status — breastfeeding is a separate question from pregnancy, and the risk profile is different. Botulinum toxin is a large molecule unlikely to enter breast milk in clinically significant amounts, but there is no safety data, and most practices defer treatment until breastfeeding is complete. HA fillers are generally considered compatible with breastfeeding since HA is a naturally occurring substance and injections are localized, but practice policies vary. Your consent should document your practice's specific policy on breastfeeding patients rather than leaving it to individual provider judgment.
- Fertility treatment status — patients undergoing IVF or other fertility treatments may be on hormonal medications that affect treatment outcomes, and they may become pregnant between the intake visit and the treatment visit. Your form should ask about active fertility treatment and establish a protocol for re-screening pregnancy status at each visit.
- Last menstrual period — for patients of childbearing potential, documenting LMP provides a clinical data point for pregnancy screening without requiring a pregnancy test for every visit (though some practices require testing for certain procedures). It also provides context for hormonal fluctuations that can affect treatment outcomes — some patients experience increased bruising and skin sensitivity during certain phases of the menstrual cycle.
- Contraception status — hormonal contraceptives can contribute to melasma, which affects treatment planning for patients seeking pigmentation correction. This is not about judging the patient's reproductive choices — it is about understanding hormonal influences on the skin condition you are being asked to treat. A patient on combined oral contraceptives who wants laser treatment for melasma has a recurrence risk that the provider must discuss honestly.
Treatment combination restrictions and cooling periods
Patients in medical spas frequently want multiple treatments, and the current marketing culture encourages "combination treatments" and "treatment stacking." But not every combination is safe, and the timing between treatments matters clinically. Your intake form must capture enough information for the provider to assess combination safety.
- Current treatment plan — what treatments has the patient received in the past 30 days? 90 days? This includes treatments received at other practices, which the patient may not think to mention. A patient who received microneedling at another practice last week and now wants a chemical peel at yours is asking for a double insult to the skin barrier that increases complication risk.
- Planned treatments — is the patient planning other procedures (surgical or non-surgical) in the coming weeks? A patient who is having rhinoplasty next month should not receive nasal filler this month. A patient who has a wedding in two weeks should not receive a medium-depth chemical peel, regardless of how much she wants to "look refreshed."
- Cooling period documentation — your intake should reference your practice's cooling period protocols: minimum time between neurotoxin and filler in the same area, minimum time between laser treatments and chemical peels, minimum time between microneedling and any other procedure. These cooling periods exist because combining treatments without adequate recovery time compounds tissue stress and multiplies complication risk in ways that are not simply additive.
- Concurrent medication changes — a patient who just started a new medication (particularly retinoids, antibiotics, or immunosuppressants) since her last visit may have a changed risk profile. Your intake process should re-screen medication status at every visit, not just at the initial intake. This is where a simple "anything changed since your last visit?" question on a streamlined return-visit form captures critical safety information.
Adverse event documentation and reporting requirements
When something goes wrong — and in a high-volume medical spa, something will eventually go wrong — your documentation determines whether the event is manageable or catastrophic. Adverse event documentation starts at intake, not at the moment of the complication.
- Baseline documentation — your pre-treatment intake and photographs establish the baseline. When a patient claims a complication, your baseline documentation proves what the tissue looked like before you touched it. Without baseline photos and a documented pre-treatment skin assessment, the patient's claim is unopposed.
- Treatment record integration — your intake form should be designed to integrate with a treatment record that documents: product used (name, lot number, expiration date), units or volume injected, injection sites (marked on a face diagram), device settings for laser treatments (fluence, pulse duration, spot size, cooling parameters), provider identity, and any immediate adverse reactions observed.
- Adverse event classification — your documentation system should support classification of adverse events by severity: expected side effects (bruising, swelling, erythema), minor complications (asymmetry requiring touch-up, prolonged erythema), moderate complications (infection, nodule formation, delayed hypersensitivity), and severe complications (vascular occlusion, tissue necrosis, vision changes, anaphylaxis). Each classification level should trigger a different response protocol.
- FDA MedWatch reporting — adverse events related to FDA-regulated products (injectables, laser devices) may require or benefit from MedWatch reporting. Your documentation system should support the data collection needed for a MedWatch submission: product identification, lot number, patient demographics, event description, event date, outcome, and contributing factors. Practices that report adverse events contribute to post-market surveillance and demonstrate a commitment to patient safety that also serves as evidence of a quality-conscious practice culture in any subsequent litigation.
- State reporting obligations — some states require reporting of certain adverse events to the medical board, especially events involving non-physician providers working under delegation. Your medical director needs to know about these events promptly, and your documentation system must support rapid notification. The intake form establishes the data infrastructure that makes event reporting possible: without the patient's baseline health information, medication list, and treatment history documented at intake, you cannot complete a meaningful adverse event report.
Putting it together: intake as risk management infrastructure
A medical spa intake form is not a piece of paperwork that patients sign while waiting for their appointment. It is the clinical, legal, and regulatory foundation of every treatment you perform. It screens for contraindications that prevent complications. It documents informed consent that protects your practice in litigation. It establishes the baseline records that adverse event reporting depends on. It proves that your medical director's oversight protocols are actually implemented, not just written in a policy manual that nobody reads.
The practices that get this right — that invest in structured, procedure-specific intake documentation — are the practices that sleep at night. The practices that hand patients a generic waiver and hope for the best are one vascular occlusion event away from a lawsuit that their documentation cannot defend.
Your patients chose your medical spa because they want professional results in a professional environment. Your intake documentation should reflect that same standard. The patient who fills out a thorough, well-designed intake form understands that she is receiving medical care from qualified providers who take her safety seriously. That is the message your intake process should send before the first syringe is uncapped.
If you are building or upgrading your intake documentation for a healthcare practice, the Healthcare Bundle includes medical spa forms alongside 20 other healthcare specialties, each with profession-specific intake fields designed for clinical environments that handle both medical risk management and patient experience.
Medical Spa & Aesthetics intake forms — $19.99 complete set
Fillable PDF intake form + client questionnaire. Medical history screening, Fitzpatrick skin typing, injectable consent, laser protocol documentation, photography releases, allergy screening, adverse event tracking, and regulatory compliance fields. Built for medical spas and aesthetic practices.
Not ready to buy? Download our free Universal Intake Form — a fillable PDF you can use today, no purchase needed.